Clinical Trial Goal
To find out:
- The highest dose of iberdomide that’s safe to give with teclistamab
- If the combination of iberdomide and teclistamab is safe and works well to treat multiple myeloma that has relapsed or is refractory
You may be able to join this trial if you:
- Are 18 years old or older
- Have multiple myeloma that has relapsed or is refractory
- Have been treated with the following. Your doctor can tell you this:
- A CD38 monoclonal antibody, like daratumumab or isatuximab
- An immunomodulatory drug, like lenalidomide, pomalidomide or thalidomide
- A proteasome inhibitor, like bortezomib, carfilzomib or ixazomib
- Do not have any of the following:
- Active amyloid light chain amyloidosis
- POEMS syndrome
- Waldenstrom's macroglobulinemia
- Have not been treated with any of the following (your doctor can tell you this):
- E3 ligase modulator
- Have not had allogeneic (cells from a donor) blood or marrow transplant (BMT)
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Iberdomide is a cereblon E3 ligase modulater that targets certain proteins on cancer cells.
Teclistamab is a bispecific antibody that targets BCMA and CD3 on certain cells.
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
Teclistamab is a bispecific antibody that targets BCMA and CD3 on certain cells.
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
- Iberdomide – A pill that you take by mouth 1 time each day for 3 weeks
- Teclistamab – Given as a shot under your skin 1 time each week
You may continue treatment for up to 4 years. You'll have biopsies to see how well the treatment is working. The clinical trial doctors will check your health for up to 2 years.
The Food and Drug Administration (FDA) has not yet approved iberdomide.
Locations
Sponsors
lead: National Cancer Institute (NCI)
